Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio Among Healthcare Movers
Buy Rating Maintained for Annovis Bio Ahead of Key Parkinson's Drug Trial Results
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Stocks With More Than 10% Short Interest - Finviz Screener
Express News | Annovis Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results
Annovis Bio Is Maintained at Buy by HC Wainwright & Co.
Annovis Bio Is Maintained at Buy by HC Wainwright & Co.
Annovis Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 277.67% HC Wainwright & Co. $30 → $23 Maintains Buy 04/30/2024 326.93% Canaccord Genuity $36 →
Express News | Annovis Bio's Cash And Cash Equivalents Totaled $3.1M As Of March 31, 2024, Will Fund Its Operations Into The Fourth Quarter Of 2024
Express News | Annovis Bio Q1 2024 GAAP EPS $(0.72) Beats $(0.86) Estimate
Express News | Annovis Bio Inc - Estimates Cash and Working Capital Positions Will Fund Its Operations Into Q4 of 2024
Buy Rating Reaffirmed for Annovis Bio Amid Positive Prospects for Parkinson's Treatment
Express News | Annovis Bio, Inc. : H.c. Wainwright Cuts Target Price to $23 From $30
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
Mon, 13 May 2024MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Annovis Bio | 10-Q: Quarterly report
Express News | Annovis Reports Completion Of Data Cleaning For Phase III Study Of Buntanetap In Patients With Early Parkinson's Disease; Topline Efficacy Data Is Expected In June
Express News | Annovis Bio Inc - Topline Efficacy Data Is Expected in June
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
Thu, 09 May 2024MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neur
Annovis Bio Issues Key Update on Corporate Progress
Express News | Annovis Bio - Believe FDA Will Accept Buntanetap for Symptomatic Relief,Will Allow to Continue Next Pivotal Phase III Study for Disease-Modification
No Data